Saturday, April 11, 2020

Relation between improvement of glycemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: a meta‐analysis with metaregression

Once again they missed the memo that WHO reclassified stroke in 2006, now a neurological disease not cardiovascular disease? 

If our researchers are out-of-date how do you think your stroke doctors are keeping up? Does your stroke hospital have a research analysis employee whose only job is to take stroke research and implement into interventions and train the staff in the latest? If not you don't have a stroke hospital.

The MACE definition is wrong.

Relation between improvement of glycemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: a meta‐analysis with metaregression

Diabetes, Obesity and MetabolismGiugliano D, Bellastella G, Longo M, et al. | April 08, 2020

A meta‐analysis with metaregression was conducted to disclose associations between reduction of HbA1c levels and risk of major cardiovascular events (MACE) in all cardiovascular outcome trials (CVOTs) so far published in patients with type 2 diabetes (T2D). Researchers carried out an electronic search up to February 10, 2020 to ascertain eligible trials. They evaluated pooled summary estimates and 95% confidence intervals according to random effects model applying the Paule‐Mandel method; restricted maximum likelihood estimators were applied to calculate model parameters in the metaregression. This study included 15 CVOTs involving a total of 138,250 patients. In CVOTs, the blood glucose reduction may play some role in lowering the risk of nonfatal stroke, at least during treatment with GLP‐1 RAs, without influencing the other two components of MACE.
Read the full article on Diabetes, Obesity and Metabolism

No comments:

Post a Comment